Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Urinary Bladder Neoplasms 2Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma in Situ 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × BCG Vaccine × 90 days × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05538663 2026-05-05

BRIDGE

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
870 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03711032 2026-05-01

MK-3475-676

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03528694 2026-04-14

POTOMAC

AstraZeneca

Phase 3 Active not recruiting
1,018 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05037279 2026-03-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting
540 enrolled
Genitourinary

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡